ArticleJournal of orthopaedic case reports2026
Impaired Bone Healing and Fracture Complications during Limb Lengthening in a Neurofibromatosis Type 1 Patient Receiving Selumetinib: Case Report and Literature Review.
Article in Journal of orthopaedic case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neurofibromatosis Type 1 (NF1) is a genetic disorder that may lead to the development of plexiform neurofibromas (Pns). Selumetinib, a selective mitogen-activated protein kinase (MEK1/2) inhibitor, has shown clinical benefit in shrinking inoperable PNs. However, its long-term effects on the skeleton remain unclear. This case describes impaired bone healing and pathological fractures following limb lengthening in a child with NF1 receiving prolonged selumetinib therapy. Case Report: A 5-year-old boy with genetically confirmed NF1 and left lower limb PN-induced overgrowth presented with a 4.5 cm limb length discrepancy. The patient had been receiving selumetinib (20 mg twice daily) without a clinically significant reduction in the size of the PNs. Lengthening was performed on a short healthy lower leg with an external fixator that did not include the femur. A distal femoral fracture occurred 3 weeks postoperatively on the same side as the lower leg lengthening was performed, and was treated with K-wire fixation. Despite healing, a refracture occurred 2 months later. In addition, delayed bone healing was observed for the tibial lengthening regenerate, and progressive valgus deformity and fibular migration developed. Selumetinib was discontinued due to adverse effects and suspected contribution to impaired bone healing. Conclusion: In pediatric NF1 patients treated with selumetinib, fracture and impaired bone healing may be rare side effects, especially during limb lengthening. These findings highlight the importance of closely monitoring bone health in NF1 patients on MEK inhibitors, particularly when undergoing orthopedic procedures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.